Mechanism-Based Therapies for the Treatment of Portal Hypertension

Nov 16 2024
Convention Center: Ballroom 6A
8:00 AM - 9:30 AM
Captured

World Class Speakers

Jordi Gracia-Sancho, PhD, FAASLD
Presenter

Jordi Gracia-Sancho, PhD, FAASLD

IDIBAPS - Hospital Clínic Barcelona
Tamar Taddei, MD, MD, FAASLD
Presenter

Tamar Taddei, MD, MD, FAASLD

Yale University
Mattias Mandorfer, MD PhD
Presenter

Mattias Mandorfer, MD PhD

Medical University of Vienna
Lise Lotte L Gluud
Presenter

Lise Lotte L Gluud

Copenhagen University Hospital Hvidovre
Atoosa Rabiee, MD, MD
Moderator

Atoosa Rabiee, MD, MD

Washington DC VA Medical Center

Description

Organized by the portal hypertension SIG, this session provides an update on new therapies based on the mechanisms of portal hypertension and chronic liver disease, with special emphasis on current knowledge regarding relevant pathophysiology, new preclinical and clinical data, and controversies in the field.

Journey Maps

ALD

Objectives

  • Describe the cellular and molecular mechanisms of portal hypertension in the context of chronic liver disease.
  • Review the data regarding current and potential therapeutic options for portal hypertension including pharmacologic and interventional approaches.
Chair

Don Rockey, MD, FAASLD